Stoke Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended September 30, 2026, none of our directors or officers, as defined in Rule 16a-1(f), informed us of theadoption, modification ortermination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
| Name · Title · Action · Date · Rule 10b5-1* · Non Rule 10b5-1** · Total Shares to be Sold · Expiration Date(1) | ||||||
|---|---|---|---|---|---|---|
| Edward Kaye⁽²⁾ | Former Director | Terminated | 9/24/2026 | X | 470,874 | 05/31/2027 |
*Intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Act.
**Not intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Act.
(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier of (a) the completion of all purchases or sales or (b) the date listed in the table.
(2) On September 22, 2026, Edward Kaye notified the Company of his resignation from the board of directors of the Company, effective September 23, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.